Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ (710)	$ 372
BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		(473)
Allogene and BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities			$ 409
BioNTech [Member] | Collaborative Arrangement [Member]
Loss Contingencies [Line Items]
Proceeds from collaborators		$ 188

[1] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of April 3, 2022, there were cumulative impairments and downward adjustments of $110 million and upward adjustments of $167 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2022 and 2021.